India In-Vitro Diagnostics Market Size and Share

Name: India In-Vitro Diagnostics Market Size and Share | 2024–2030
Creator: Supradip Baul
Published: Sep 2025

Download Now

India In-Vitro Diagnostics Market by Product & Service (Reagents & Consumables, Instruments & Devices, and Software & Services), by Technique (Clinical Chemistry, Immunoassays, Molecular Diagnostics, and Other Techniques), by Testing Site / Channel (Central & Reference Laboratories, Hospital & Physician Labs, Point-of-Care & Retail, and Others), by Application / Disease Area (Infectious Diseases, Oncology, Cardiovascular Health, and Others)– Opportunity Analysis and Industry Forecast, 2024–2030.

Download PDF

Speak to Our Analyst

Market In-Vitro Diagnostics Market Overview

The India In-Vitro Diagnostics Market size was valued at USD 2.64 billion in 2023, and is predicted to reach USD 4.40 billion by 2030, at a CAGR of 7.17% from 2024 to 2030. In-vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions.

Immunodiagnostic tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology.
These tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, IVD tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics.

Also, in-vitro experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges.

Strong Growth of India’s Medical Device Industry Drives Market Expansion

India’s medical device industry is experiencing rapid growth, fueling the expansion of the in-vitro diagnostics market. Recognized as a sunrise sector in the country’s economy, the medical device market has seen rising investments in healthcare infrastructure and technology. This momentum is supported by increasing exports and a growing global demand for Indian-made healthcare products, positioning the sector for sustained growth.

As medical devices evolve and integrate advanced technologies, the adoption of innovative diagnostic solutions like in-vitro diagnostics is accelerating. This growth is expected to enhance the accessibility, affordability, and quality of diagnostic services across India, supporting the broader goal of modernizing healthcare delivery nationwide.

Rising Cancer Incidence in India Accelerates Market Demand

The increasing burden of cancer in India is a critical factor driving demand for advanced in-vitro diagnostic solutions. With over 1.4 million new cancer cases reported annually, there is a pressing need for accurate and timely diagnosis to improve patient outcomes and guide personalized treatment strategies.

Immunodiagnostic technologies, essential for detecting and monitoring various cancers, are witnessing growing adoption. These tools support early detection and continuous disease monitoring, which are vital for effective cancer management and improving survival rates in the Indian population.

High R&D and Regulatory Costs Challenge Market Growth

Significant costs related to research, development, and regulatory approvals pose challenges to the expansion of India’s IVD market. Developing reliable diagnostic products requires extensive clinical validation and compliance with rigorous quality standards, demanding substantial financial and time investments from manufacturers.

Moreover, navigating complex regulatory frameworks adds to the operational burden for companies. The stringent approval process, aimed at ensuring safety and efficacy, can slow down product launches and limit the entry of new innovations, restricting market growth.

Expansion of Point-of-Care Testing Drives New Opportunities

Point-of-care testing (POCT) is rapidly emerging as a key growth area within India’s IVD market. These portable, rapid testing solutions enable immediate diagnostic results in diverse settings such as emergency rooms, rural clinics, and mobile healthcare units, addressing urgent healthcare needs efficiently.

By complementing traditional laboratory diagnostics, POCT enhances healthcare providers’ ability to make quick, informed decisions. This integration improves patient care through faster diagnosis and treatment initiation, ultimately boosting the overall efficiency and effectiveness of healthcare services across the country.

Competitive Landscape

The promising players operating in the India in-vitro diagnostics industry include Roche Diagnostics India Private Limited, Abbott Healthcare Private Limited, Siemens Healthineers India Private Limited, Beckman Coulter India Pvt. Ltd. (Danaher Group), Thermo Fisher Scientific India Pvt. Ltd., Sysmex India Pvt. Ltd, bioMérieux India Private Limited, Transasia Bio-Medicals Ltd., Agappe Diagnostics Ltd., Bio-Rad Laboratories (India) Pvt. Ltd., J. Mitra & Co. Pvt. Ltd., Hologic India LLP, Molbio Diagnostics Pvt. Ltd., Mylab Discovery Solutions Pvt. Ltd., Becton Dickinson India Pvt. Ltd., and others.

India In-Vitro Diagnostics Market Key Segments

By Product & Service

Reagents & Consumables
- Clinical Chemistry Reagents
- Immunoassay Reagents (ELISA/CLIA)
- Molecular Master Mixes
- Hematology Controls
Instruments & Devices
- Chemistry Analyzers
- Immunoassay Systems
- Molecular Thermocyclers/Sequencers
- Hematology Analyzers
- POC Devices
Software & Services
- LIS, Data Analytics
- CRO/Testing Services

By Technique

Clinical Chemistry
- Metabolites
- Electrolytes
- Enzymes
Immunoassays
- ELISA / CLIA / CMIA
- Lateral-flow Rapid Tests
- Immunofluorescence
Molecular Diagnostics
- PCR
- Isothermal NAAT
- NGS
- In-situ Hybridization
Hematology & Coagulation
- CBC Analyzers
- Coagulation Panels
Microbiology
- Culture & Sensitivity
- MALDI-TOF
- Molecular ID
Urinalysis & Body Fluids
Other Techniques

By Testing Site / Channel

Central & Reference Laboratories
Hospital & Physician Labs
Point-of-Care & Retail
Home & Self-Testing

By Application / Disease Area

Infectious Diseases
Oncology
Cardiovascular Health
Endocrinology & Diabetes
Nephrology
Genetic & Prenatal Testing
Autoimmune Disorders
Drug Monitoring & Toxicology
Blood Screening & Typing
Other Indications

Key Players

Roche Diagnostics India Private Limited
Abbott Healthcare Private Limited
Siemens Healthineers India Private Limited
Beckman Coulter India Pvt. Ltd. (Danaher Group)
Thermo Fisher Scientific India Pvt. Ltd.
Sysmex India Pvt. Ltd
bioMérieux India Private Limited
Transasia Bio-Medicals Ltd.
Agappe Diagnostics Ltd.
Bio-Rad Laboratories (India) Pvt. Ltd.
J. Mitra & Co. Pvt. Ltd.
Hologic India LLP
Molbio Diagnostics Pvt. Ltd.
Mylab Discovery Solutions Pvt. Ltd.
Becton Dickinson India Pvt. Ltd.

REPORT SCOPE AND SEGMENTATION:

Parameters	Details
Market Size Value in 2023	USD 2.64 billion
Revenue Forecast in 2030	USD 4.40 billion
Value Growth Rate	CAGR of 7.17% from 2024 to 2030
Analysis Period	2023–2030
Base Year Considered	2023
Forecast Period	2024–2030
Market Size Estimation	Billion (USD)
Growth Factors	Strong Growth of India’s Medical Device Industry Drives Market Expansion Rising Cancer Incidence in India Accelerates Market Demand
Companies Profiled	15
Customization Scope	Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs.

1. 1.1 REPORT DESCRIPTION
2. 1.2 RESEARCH METHODOLOGY
3. 1. 1.2.1 SECONDARY RESEARCH
  2. 1.2.2 DATA ANALYSIS FRAMEWORK
  3. 1.2.3 MARKET SIZE ESTIMATION
  4. 1.2.4 FORECASTING
  5. 1.2.5 PRIMARY RESEARCH AND DATA VALIDATION

1. 2.1. MARKET SNAPSHOT, 2024 - 2030, BILLION USD

1. 3.1 BARGAINING POWER OF SUPPLIERS
2. 3.2 BARGAINING POWER OF BUYERS
3. 3.3 DEGREE OF COMPETITION
4. 3.4 THREAT OF SUBSTITUTE
5. 3.5 THREAT OF NEW ENTRANTS

1. 4.1 MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2024

1. 5.1 GROWTH DRIVERS
2. 1. 5.1.1 STRONG GROWTH OF INDIA'S MEDICAL DEVICE INDUSTRY FUELS MARKET EXPANSION
  2. 5.1.2 INCREASING PREVALENCE OF CANCER IN INDIA BOOSTS MARKET GROWTH
3. 5.2 CHALLENGES
4. 1. 5.2.1 HIGH RESEARCH, DEVELOPMENT, AND REGULATORY APPROVAL COSTS HINDER THE MARKET GROWTH
5. 5.3 OPPORTUNITIES
6. 1. 5.3.1 INTRODUCTION OF POINT-OF-CARE TESTING SOLUTIONS IN IVD CREATES MARKET OPPORTUNITY 6 INDIA IN VITRO DIAGONOSTIC MARKET BY PRODUCT TYPE
7. 6.1 OVERVIEW
8. 6.2 REAGENTS MARKET
9. 6.3 INSTRUMENTS MARKET
10. 6.4 SOFTWARE AND SERVICES MARKET

1. 7.1 OVERVIEW
2. 7.2 IMMUNODIAGNOSTICS MARKET
3. 1. 7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
  2. 7.2.2 RAPID TESTS
  3. 7.2.3 CHEMILUMINESCENCE IMMUNOASSAY (CLIA)
  4. 7.2.4 ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT)
  5. 7.2.5 RADIOIMMUNOASSAY (RIA)
  6. 7.2.6 WESTERN BLOT
4. 7.3 HEMATOLOGY MARKET
5. 7.4 MOLECULAR DIAGNOSTICS MARKET
6. 1. 7.4.1 PCR
  2. 1. 7.4.1.1 MONOPLEX PCR
    2. 7.4.1.2 MULTIPLEX PCR
  3. 7.4.2 INAAT
  4. 7.4.3 HYBRIDIZATION
  5. 7.4.4 DNA DIAGNOSTICS
  6. 7.4.5 MICROARRAY
  7. 7.4.6 OTHER MOLECULAR DIAGNOSTICS
7. 7.5 TISSUE DISGNOSTICS MARKET
8. 7.6 CLINICAL CHEMISTRY MARKET
9. 1. 7.6.1 BASIC METABOLIC PANEL
  2. 7.6.2 LIVER PANEL
  3. 7.6.3 RENAL PROFILE
  4. 7.6.4 LIPID PROFILE
  5. 7.6.5 THYROID FUNCTION PANEL
  6. 7.6.6 ELECTROLYTE PANEL
  7. 7.6.7 SPECIALITY CHEMICALS
10. 7.7 OTHER IVD TECHNIQUES MARKET

1. 8.1 OVERVIEW
2. 8.2 INFECTIOUS DISEASES MARKET
3. 8.3 CANCER MARKET
4. 8.4 CARDIAC DISEASES MARKET
5. 8.5 IMMUNE SYSTEM DISORDERS MARKET
6. 8.6 NEPHROLOGICAL DISEASES MARKET
7. 8.7 GASTROINTESTINAL DISEASES MARKET
8. 8.8 OTHER INDICATIONS MARKET

1. 9.1 OVERVIEW
2. 9.2 STAND ALONE LABORATORY MARKET
3. 9.3 HOSPITALS MARKET
4. 9.4 ACADEMICS AND MEDICAL SCHOOLS MARKET
5. 9.5 POINT OF CARE TESTING MARKET
6. 9.6 OTHER END-USERS MARKET

1. 10.1 ABBOTT LABORATORIES
2. 1. 10.1.1 COMPANY OVERVIEW
  2. 10.1.2 COMPANY SNAPSHOT
  3. 10.1.3 OPERATING BUSINESS SEGMENTS
  4. 10.1.4 PRODUCT PORTFOLIO
  5. 10.1.5 BUSINESS PERFORMANCE
  6. 10.1.6 BUSINESS SEGMENTS
  7. 10.1.7 GEOGRAPHIC SEGMENTS
  8. 10.1.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.1.9 PRIMARY MARKET COMPETITORS
3. 10.2 ROCHE HOLDING AG
4. 1. 10.2.1 COMPANY OVERVIEW
  2. 10.2.2 COMPANY SNAPSHOT
  3. 10.2.3 OPERATING BUSINESS SEGMENTS
  4. 10.2.4 PRODUCT PORTFOLIO
  5. 10.2.5 BUSINESS PERFORMANCE
  6. 10.2.6 BUSINESS SEGMENTS
  7. 10.2.7 GEOGRAPHIC SEGMENTS
  8. 10.2.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.2.9 PRIMARY MARKET COMPETITORS
5. 10.3 MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.
6. 1. 10.3.1 COMPANY OVERVIEW
  2. 10.3.2 COMPANY SNAPSHOT
  3. 10.3.3 OPERATING BUSINESS SEGMENTS
  4. 10.3.4 PRODUCT PORTFOLIO
  5. 10.3.5 BUSINESS PERFORMANCE
  6. 10.3.6 BUSINESS SEGMENTS
  7. 10.3.7 GEOGRAPHIC SEGMENTS
  8. 10.3.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.3.9 PRIMARY MARKET COMPETITORS
7. 10.4 THERMO FISHER SCIENTIFIC INC
8. 1. 10.4.1 COMPANY OVERVIEW
  2. 10.4.2 COMPANY SNAPSHOT
  3. 10.4.3 OPERATING BUSINESS SEGMENTS
  4. 10.4.4 PRODUCT PORTFOLIO
  5. 10.4.5 BUSINESS PERFORMANCE
  6. 10.4.6 BUSINESS SEGMENTS
  7. 10.4.7 GEOGRAPHIC SEGMENTS
  8. 10.4.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.4.9 PRIMARY MARKET COMPETITORS
9. 10.5 DANAHER CORPORATION
10. 1. 10.5.1 COMPANY OVERVIEW
  2. 10.5.2 COMPANY SNAPSHOT
  3. 10.5.3 OPERATING BUSINESS SEGMENTS
  4. 10.5.4 PRODUCT PORTFOLIO
  5. 10.5.5 BUSINESS PERFORMANCE
  6. 10.5.6 BUSINESS SEGMENTS
  7. 10.5.7 GEOGRAPHIC SEGMENTS
  8. 10.5.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.5.9 PRIMARY MARKET COMPETITORS
11. 10.6 BECTON, DICKINSON AND COMPANY
12. 1. 10.6.1 COMPANY OVERVIEW
  2. 10.6.2 COMPANY SNAPSHOT
  3. 10.6.3 OPERATING BUSINESS SEGMENTS
  4. 10.6.4 PRODUCT PORTFOLIO
  5. 10.6.5 BUSINESS PERFORMANCE
  6. 10.6.6 BUSINESS SEGMENTS
  7. 10.6.7 GEOGRAPHIC SEGMENTS
  8. 10.6.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.6.9 PRIMARY MARKET COMPETITORS
13. 10.7 SIEMENS HEALTHINEERS AG
14. 1. 10.7.1 COMPANY OVERVIEW
  2. 10.7.2 COMPANY SNAPSHOT
  3. 10.7.3 OPERATING BUSINESS SEGMENTS
  4. 10.7.4 PRODUCT PORTFOLIO
  5. 10.7.5 BUSINESS PERFORMANCE
  6. 10.7.6 BUSINESS SEGMENTS
  7. 10.7.7 GEOGRAPHIC SEGMENTS
  8. 10.7.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.7.9 PRIMARY MARKET COMPETITORS
15. 10.8 BIOMÉRIEUX SA
16. 1. 10.8.1 COMPANY OVERVIEW
  2. 10.8.2 COMPANY SNAPSHOT
  3. 10.8.3 OPERATING BUSINESS SEGMENTS
  4. 10.8.4 PRODUCT PORTFOLIO
  5. 10.8.5 BUSINESS PERFORMANCE
  6. 10.8.6 BUSINESS SEGMENTS
  7. 10.8.7 GEOGRAPHIC SEGMENTS
  8. 10.8.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.8.9 PRIMARY MARKET COMPETITORS
17. 10.9 SYSMEX CORPORATION
18. 1. 10.9.1 COMPANY OVERVIEW
  2. 10.9.2 COMPANY SNAPSHOT
  3. 10.9.3 OPERATING BUSINESS SEGMENTS
  4. 10.9.4 PRODUCT PORTFOLIO
  5. 10.9.5 BUSINESS PERFORMANCE
  6. 10.9.6 BUSINESS SEGMENTS
  7. 10.9.7 GEOGRAPHIC SEGMENTS
  8. 10.9.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.9.9 PRIMARY MARKET COMPETITORS
19. 10.10 QIAGEN N.V.
20. 1. 10.10.1 COMPANY OVERVIEW
  2. 10.10.2 COMPANY SNAPSHOT
  3. 10.10.3 OPERATING BUSINESS SEGMENTS
  4. 10.10.4 PRODUCT PORTFOLIO
  5. 10.10.5 BUSINESS PERFORMANCE
  6. 10.10.6 BUSINESS SEGMENTS
  7. 10.10.7 GEOGRAPHIC SEGMENTS
  8. 10.10.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.10.9 PRIMARY MARKET COMPETITORS
21. 10.11 BIO-RAD LABORATORIES, INC.
22. 1. 10.11.1 COMPANY OVERVIEW
  2. 10.11.2 COMPANY SNAPSHOT
  3. 10.11.3 OPERATING BUSINESS SEGMENTS
  4. 10.11.4 PRODUCT PORTFOLIO
  5. 10.11.5 BUSINESS PERFORMANCE
  6. 10.11.6 BUSINESS SEGMENTS
  7. 10.11.7 GEOGRAPHIC SEGMENTS
  8. 10.11.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.11.9 PRIMARY MARKET COMPETITORS
23. 10.12 PROTON BIOLOGICALS INDIA
24. 1. 10.12.1 COMPANY OVERVIEW
  2. 10.12.2 COMPANY SNAPSHOT
  3. 10.12.3 OPERATING BUSINESS SEGMENTS
  4. 10.12.4 PRODUCT PORTFOLIO
  5. 10.12.5 BUSINESS PERFORMANCE
  6. 10.12.6 BUSINESS SEGMENTS
  7. 10.12.7 GEOGRAPHIC SEGMENTS
  8. 10.12.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.12.9 PRIMARY MARKET COMPETITORS
25. 10.13 NIHON KOHDEN CORPORATION
26. 1. 10.13.1 COMPANY OVERVIEW
  2. 10.13.2 COMPANY SNAPSHOT
  3. 10.13.3 OPERATING BUSINESS SEGMENTS
  4. 10.13.4 PRODUCT PORTFOLIO
  5. 10.13.5 BUSINESS PERFORMANCE
  6. 10.13.6 BUSINESS SEGMENTS
  7. 10.13.7 GEOGRAPHIC SEGMENTS
  8. 10.13.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.13.9 PRIMARY MARKET COMPETITORS
27. 10.14 DIASORIN
28. 1. 10.14.1 COMPANY OVERVIEW
  2. 10.14.2 COMPANY SNAPSHOT
  3. 10.14.3 OPERATING BUSINESS SEGMENTS
  4. 10.14.4 PRODUCT PORTFOLIO
  5. 10.14.5 BUSINESS PERFORMANCE
  6. 10.14.6 BUSINESS SEGMENTS
  7. 10.14.7 GEOGRAPHIC SEGMENTS
  8. 10.14.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.14.9 PRIMARY MARKET COMPETITORS
29. 10.15 AGILENT TECHNOLOGIES, INC
30. 1. 10.15.1 COMPANY OVERVIEW
  2. 10.15.2 COMPANY SNAPSHOT
  3. 10.15.3 OPERATING BUSINESS SEGMENTS
  4. 10.15.4 PRODUCT PORTFOLIO
  5. 10.15.5 BUSINESS PERFORMANCE
  6. 10.15.6 BUSINESS SEGMENTS
  7. 10.15.7 GEOGRAPHIC SEGMENTS
  8. 10.15.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.15.9 PRIMARY MARKET COMPETITORS

TABLE 1. INDIA IN VITRO DIAGONOSTIC MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (BILLION USD)
TABLE 2. REAGENTS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 3. INSTRUMENTS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 4. SOFTWARE AND SERVICES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 5. INDIA IN VITRO DIAGONOSTIC MARKET VALUE, BY TECHNIQUE, 2024-2030, (BILLION USD)
TABLE 6. IMMUNODIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 7. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 8. RAPID TESTS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 9. CHEMILUMINESCENCE IMMUNOASSAY (CLIA), MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 10. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT), MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 11. RADIOIMMUNOASSAY (RIA), MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 12. WESTERN BLOT, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 13. HEMATOLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 14. MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 15. PCR, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 16. INAAT, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 17. HYBRIDIZATION, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 18. DNA DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 19. MICROARRAY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 20. OTHER MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 21. TISSUE DISGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 22. CLINICAL CHEMISTRY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 23. BASIC METABOLIC PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 24. LIVER PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 25. RENAL PROFILE, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 26. LIPID PROFILE, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 27. THYROID FUNCTION PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 28. ELECTROLYTE PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 29. SPECIALITY CHEMICALS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 30. OTHER IVD TECHNIQUES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 31. INDIA IN VITRO DIAGONOSTIC MARKET VALUE, BY APPLICATION, 2024-2030, (BILLION USD)
TABLE 32. INFECTIOUS DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 33. CANCER, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 34. CARDIAC DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 35. IMMUNE SYSTEM DISORDERS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 36. NEPHROLOGICAL DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 37. GASTROINTESTINAL DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 38. OTHER INDICATIONS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 39. INDIA IN VITRO DIAGONOSTIC MARKET VALUE, BY END-USER, 2024-2030, (BILLION USD)
TABLE 40. STAND ALONE LABORATORY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 41. HOSPITALS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 42. ACADEMICS AND MEDICAL SCHOOLS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 43. POINT OF CARE TESTING, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 44. OTHER END-USERS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 45. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 46. ABBOTT LABORATORIES: OPERATING BUSINESS SEGMENTS
TABLE 47. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 48. ABBOTT LABORATORIES: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 49. ABBOTT LABORATORIES: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 50. ABBOTT LABORATORIES: KEY STRATERGY
TABLE 51. ROCHE HOLDING AG: COMPANY SNAPSHOT
TABLE 52. ROCHE HOLDING AG: OPERATING BUSINESS SEGMENTS
TABLE 53. ROCHE HOLDING AG: PRODUCT PORTFOLIO
TABLE 54. ROCHE HOLDING AG: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 55. ROCHE HOLDING AG: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 56. ROCHE HOLDING AG: KEY STRATERGY
TABLE 57. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: COMPANY SNAPSHOT
TABLE 58. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: OPERATING BUSINESS SEGMENTS
TABLE 59. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: PRODUCT PORTFOLIO
TABLE 60. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 61. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 62. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: KEY STRATERGY
TABLE 63. THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT
TABLE 64. THERMO FISHER SCIENTIFIC INC: OPERATING BUSINESS SEGMENTS
TABLE 65. THERMO FISHER SCIENTIFIC INC: PRODUCT PORTFOLIO
TABLE 66. THERMO FISHER SCIENTIFIC INC: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 67. THERMO FISHER SCIENTIFIC INC: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 68. THERMO FISHER SCIENTIFIC INC: KEY STRATERGY
TABLE 69. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 70. DANAHER CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 71. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 72. DANAHER CORPORATION: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 73. DANAHER CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 74. DANAHER CORPORATION: KEY STRATERGY
TABLE 75. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
TABLE 76. BECTON, DICKINSON AND COMPANY: OPERATING BUSINESS SEGMENTS
TABLE 77. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
TABLE 78. BECTON, DICKINSON AND COMPANY: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 79. BECTON, DICKINSON AND COMPANY: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 80. BECTON, DICKINSON AND COMPANY: KEY STRATERGY
TABLE 81. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
TABLE 82. SIEMENS HEALTHINEERS AG: OPERATING BUSINESS SEGMENTS
TABLE 83. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO
TABLE 84. SIEMENS HEALTHINEERS AG: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 85. SIEMENS HEALTHINEERS AG: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 86. SIEMENS HEALTHINEERS AG: KEY STRATERGY
TABLE 87. BIOMéRIEUX SA: COMPANY SNAPSHOT
TABLE 88. BIOMéRIEUX SA: OPERATING BUSINESS SEGMENTS
TABLE 89. BIOMéRIEUX SA: PRODUCT PORTFOLIO
TABLE 90. BIOMéRIEUX SA: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 91. BIOMéRIEUX SA: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 92. BIOMéRIEUX SA: KEY STRATERGY
TABLE 93. SYSMEX CORPORATION: COMPANY SNAPSHOT
TABLE 94. SYSMEX CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 95. SYSMEX CORPORATION: PRODUCT PORTFOLIO
TABLE 96. SYSMEX CORPORATION: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 97. SYSMEX CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 98. SYSMEX CORPORATION: KEY STRATERGY
TABLE 99. QIAGEN N.V.: COMPANY SNAPSHOT
TABLE 100. QIAGEN N.V.: OPERATING BUSINESS SEGMENTS
TABLE 101. QIAGEN N.V.: PRODUCT PORTFOLIO
TABLE 102. QIAGEN N.V.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 103. QIAGEN N.V.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 104. QIAGEN N.V.: KEY STRATERGY
TABLE 105. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 106. BIO-RAD LABORATORIES, INC.: OPERATING BUSINESS SEGMENTS
TABLE 107. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 108. BIO-RAD LABORATORIES, INC.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 109. BIO-RAD LABORATORIES, INC.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 110. BIO-RAD LABORATORIES, INC.: KEY STRATERGY
TABLE 111. PROTON BIOLOGICALS INDIA: COMPANY SNAPSHOT
TABLE 112. PROTON BIOLOGICALS INDIA: OPERATING BUSINESS SEGMENTS
TABLE 113. PROTON BIOLOGICALS INDIA: PRODUCT PORTFOLIO
TABLE 114. PROTON BIOLOGICALS INDIA: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 115. PROTON BIOLOGICALS INDIA: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 116. PROTON BIOLOGICALS INDIA: KEY STRATERGY
TABLE 117. NIHON KOHDEN CORPORATION: COMPANY SNAPSHOT
TABLE 118. NIHON KOHDEN CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 119. NIHON KOHDEN CORPORATION: PRODUCT PORTFOLIO
TABLE 120. NIHON KOHDEN CORPORATION: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 121. NIHON KOHDEN CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 122. NIHON KOHDEN CORPORATION: KEY STRATERGY
TABLE 123. DIASORIN: COMPANY SNAPSHOT
TABLE 124. DIASORIN: OPERATING BUSINESS SEGMENTS
TABLE 125. DIASORIN: PRODUCT PORTFOLIO
TABLE 126. DIASORIN: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 127. DIASORIN: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 128. DIASORIN: KEY STRATERGY
TABLE 129. AGILENT TECHNOLOGIES, INC: COMPANY SNAPSHOT
TABLE 130. AGILENT TECHNOLOGIES, INC: OPERATING BUSINESS SEGMENTS
TABLE 131. AGILENT TECHNOLOGIES, INC: PRODUCT PORTFOLIO
TABLE 132. AGILENT TECHNOLOGIES, INC: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 133. AGILENT TECHNOLOGIES, INC: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 134. AGILENT TECHNOLOGIES, INC: KEY STRATERGY

FIGURE 1. BARGAINING POWER OF SUPPLIERS
FIGURE 2. BARGAINING POWER OF BUYERS
FIGURE 3. DEGREE OF COMPETITION
FIGURE 4. THREAT OF SUBSTITUTE
FIGURE 5. THREAT OF NEW ENTRANTS
FIGURE 6. INDIA IN VITRO DIAGONOSTIC MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (BILLION USD)
FIGURE 7. REAGENTS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 8. INSTRUMENTS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 9. SOFTWARE AND SERVICES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 10. INDIA IN VITRO DIAGONOSTIC MARKET VALUE, BY TECHNIQUE, 2024-2030, (BILLION USD)
FIGURE 11. IMMUNODIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 12. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 13. RAPID TESTS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 14. CHEMILUMINESCENCE IMMUNOASSAY (CLIA), MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 15. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT), MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 16. RADIOIMMUNOASSAY (RIA), MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 17. WESTERN BLOT, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 18. HEMATOLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 19. MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 20. PCR, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 21. INAAT, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 22. HYBRIDIZATION, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 23. DNA DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 24. MICROARRAY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 25. OTHER MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 26. TISSUE DISGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 27. CLINICAL CHEMISTRY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 28. BASIC METABOLIC PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 29. LIVER PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 30. RENAL PROFILE, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 31. LIPID PROFILE, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 32. THYROID FUNCTION PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 33. ELECTROLYTE PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 34. SPECIALITY CHEMICALS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 35. OTHER IVD TECHNIQUES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 36. INDIA IN VITRO DIAGONOSTIC MARKET VALUE, BY APPLICATION, 2024-2030, (BILLION USD)
FIGURE 37. INFECTIOUS DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 38. CANCER, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 39. CARDIAC DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 40. IMMUNE SYSTEM DISORDERS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 41. NEPHROLOGICAL DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 42. GASTROINTESTINAL DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 43. OTHER INDICATIONS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 44. INDIA IN VITRO DIAGONOSTIC MARKET VALUE, BY END-USER, 2024-2030, (BILLION USD)
FIGURE 45. STAND ALONE LABORATORY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 46. HOSPITALS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 47. ACADEMICS AND MEDICAL SCHOOLS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 48. POINT OF CARE TESTING, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 49. OTHER END-USERS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 50. ABBOTT LABORATORIES: NET SALES, (2022-2024)
FIGURE 51. ABBOTT LABORATORIES: PRIMARY MARKET COMPETITORS
FIGURE 52. ROCHE HOLDING AG: NET SALES, (2022-2024)
FIGURE 53. ROCHE HOLDING AG: PRIMARY MARKET COMPETITORS
FIGURE 54. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: NET SALES, (2022-2024)
FIGURE 55. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: PRIMARY MARKET COMPETITORS
FIGURE 56. THERMO FISHER SCIENTIFIC INC: NET SALES, (2022-2024)
FIGURE 57. THERMO FISHER SCIENTIFIC INC: PRIMARY MARKET COMPETITORS
FIGURE 58. DANAHER CORPORATION: NET SALES, (2022-2024)
FIGURE 59. DANAHER CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 60. BECTON, DICKINSON AND COMPANY: NET SALES, (2022-2024)
FIGURE 61. BECTON, DICKINSON AND COMPANY: PRIMARY MARKET COMPETITORS
FIGURE 62. SIEMENS HEALTHINEERS AG: NET SALES, (2022-2024)
FIGURE 63. SIEMENS HEALTHINEERS AG: PRIMARY MARKET COMPETITORS
FIGURE 64. BIOMéRIEUX SA: NET SALES, (2022-2024)
FIGURE 65. BIOMéRIEUX SA: PRIMARY MARKET COMPETITORS
FIGURE 66. SYSMEX CORPORATION: NET SALES, (2022-2024)
FIGURE 67. SYSMEX CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 68. QIAGEN N.V.: NET SALES, (2022-2024)
FIGURE 69. QIAGEN N.V.: PRIMARY MARKET COMPETITORS
FIGURE 70. BIO-RAD LABORATORIES, INC.: NET SALES, (2022-2024)
FIGURE 71. BIO-RAD LABORATORIES, INC.: PRIMARY MARKET COMPETITORS
FIGURE 72. PROTON BIOLOGICALS INDIA: NET SALES, (2022-2024)
FIGURE 73. PROTON BIOLOGICALS INDIA: PRIMARY MARKET COMPETITORS
FIGURE 74. NIHON KOHDEN CORPORATION: NET SALES, (2022-2024)
FIGURE 75. NIHON KOHDEN CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 76. DIASORIN: NET SALES, (2022-2024)
FIGURE 77. DIASORIN: PRIMARY MARKET COMPETITORS
FIGURE 78. AGILENT TECHNOLOGIES, INC: NET SALES, (2022-2024)
FIGURE 79. AGILENT TECHNOLOGIES, INC: PRIMARY MARKET COMPETITORS

At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.

Research Landscape

We navigate the world of research with two primary approaches:

Qualitative Approach

Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.

Quantitative Research

In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.

Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.

Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.

Our Specialized Toolbox for Industry-Specific Market Research

We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:

Information Procurement

The stage entails acquiring market data or relevant information through various sources and methodologies.

Market Research Approach

We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.

Porters Five Forces Analysis

We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.

SWOT Analysis

We conduct SWOT analysis to understand market trends, identify potential threats, capitalize on opportunities, and assess our strengths and weaknesses.

Forecasting

We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.

Frequently Asked Questions

The India in-vitro diagnostics market revenue is estimated to reach up to USD 4.40 billion by 2030.

The key players in the India in-vitro diagnostics industry include Roche Diagnostics India Private Limited, Abbott Healthcare Private Limited, Siemens Healthineers India Private Limited, Beckman Coulter India Pvt. Ltd. (Danaher Group), Thermo Fisher Scientific India Pvt. Ltd., Sysmex India Pvt. Ltd, bioMérieux India Private Limited, Transasia Bio-Medicals Ltd., Agappe Diagnostics Ltd., Bio-Rad Laboratories (India) Pvt. Ltd., J. Mitra & Co. Pvt. Ltd., Hologic India LLP, Molbio Diagnostics Pvt. Ltd., Mylab Discovery Solutions Pvt. Ltd., Becton Dickinson India Pvt. Ltd., and others.

The India in-vitro diagnostics market size was estimated at USD 2.64 billion in 2023.

High costs associated with research, development, and regulatory approval are significant factors restraining the India IVD market growth.

Introduction of Point-of-Care Testing (POCT) solutions creates opportunities for the India in-vitro diagnostics market in the coming future.

Download Free Sample

Phone Number *

Please enter Country Code and Phone No

Yes, I have read the Privacy Policy

Multi User

$2,575

Single User

$1,575

Enterprise

$3,875

Datapack

$1,975

Download Sample

Inquire Before Buying

Speak to Our Analyst

Share with Peers

About the Author

Sikha Haritwal is a researcher with more than 5 years of experience. She has been keeping a close eye on several industry verticals, including construction & manufacturing, personal care products, and consumer electronics. She has avid interest in writing news articles and hopes to use blog as a platform to share her knowledge with others.

About the Reviewer

Supradip Baul is the CEO and Founder of Next Move Strategy Consulting, driving the firm’s mission to provide data-driven insights and strategic intelligence. With extensive experience in market research and consulting, he has helped global organizations make informed decisions and achieve sustainable growth.

Request Sample

Phone Number *

Please enter Phone No

Please Select Country